Key result
Among US females with cardiovascular disease, 12.3% were current smokers, of which only 6.9% utilized smoking cessation agents, with usage remaining persistently low from 2004 to 2011.
Observational (n=25,300,000)
The utilization of smoking cessation agents among female patients with cardiovascular disease is persistently low, particularly among non-whites and Hispanics, indicating a significant gap in preventive care.
Answers are grounded in this paper and cite their sources.
Persistent low cessation agent use in female CVD smokers highlights a care gap; leaves open whether targeted interventions can improve uptake.
BACKGROUND: In the United States, cigarette smoking accounts for almost 20% of all deaths attributed to heart disease. More women than men die each year of cardiovascular diseases (CVDs). Women who smoke have shown to be at a higher risk of cardiac deaths. The current study aims to determine the trend in smoking prevalence among women with CVD and their utilization of smoking cessation agents from 2004 to 2011. MATERIALS AND METHODS: This was a retrospective exploratory study using Medical Expenditure Panel Survey data from 2004 to 2011. All female respondents with any one cardiovascular condition were identified. Descriptive statistics were carried out to obtain the number of female patients with CVD, their smoking status, and their use of smoking cessation agents. Furthermore, disparities in smoking status and smoking cessation agent utilization with respect to race and ethnicity were studied. RESULTS: Among total CVD patients, 53% were females, which corresponded to 25.3 million females in the United States. Around 12.3% among them were current smokers. Only 6.9% among these females used smoking cessation agents. Smoking trends in females were inconsistent throughout the 8 years. Overall, the trend showed a decrease in the percentage of female smokers, while use of smoking cessation agents remained low from 2004 to 2011. Whites and non-Hispanics had more current smokers and women using smoking cessation agents. CONCLUSION: The eight-year trend shows that the use of smoking cessation agents among females is very low, particularly among non-whites and Hispanics. This is of great concern and future efforts could focus on increasing the utilization of smoking cessation agents and collectively decreasing the risk of smoking in CVD by healthcare professionals.
No takes yet. Share an insight, caveat, or question.
Vaidya et al. (2016) conducted an observational in Cardiovascular diseases (n=25,300,000). Smoking and smoking cessation agents was evaluated on Smoking prevalence and utilization of smoking cessation agents. Among US females with cardiovascular disease, 12.3% were current smokers, of which only 6.9% utilized smoking cessation agents, with usage remaining persistently low from 2004 to 2011.
Synapse has enriched 10 related papers. Consider them for comparative context: